<DOC>
	<DOCNO>NCT01304524</DOCNO>
	<brief_summary>This randomize , placebo control study determine safety efficacy VGX-3100 DNA Vaccine deliver Electroporation adult woman biopsy-proven HPV 16 18 associated Cervical intraepithelial neoplasia grade 2/3 3 .</brief_summary>
	<brief_title>A Study VGX-3100 DNA Vaccine With Electroporation Patients With Cervical Intraepithelial Neoplasia Grade 2/3 3</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>Female subject age 1855 year ; Histologically confirm HPV16 HPV18associated CIN 2/3 CIN 3 tissue collect less 10 week prior Vaccination/EP # 1 evidence invasive cancer specimen ; Colposcopy satisfactory base visualization entire squamocolumnar junction upper limit entire acetowhite suspect CIN disease area ; lesion ≤ 3 cervical quadrant ( 4 quadrant disease lesion occupy less 50 % quadrant consider inclusion ) ; Healthy subject judge Investigator base medical history , PE , normal result ECG , CBC , Serum Chemistries , CPK urinalysis do 4 week prior enrollment administration study drug ; Women childbearing potential agree remain sexually abstinent , use two medically effective method contraception ( e.g . oral contraception , barrier method , spermicide , intrauterine device ( IUD ) ) , partner sterile ( i.e. , vasectomy ) 36 week ( 9 month ) ; Able willing comply study procedure voluntarily sign inform consent form Unsatisfactory colposcopy define incomplete visualization entire squamocolumnar junction upper limit entire acetowhite suspect CIN disease area ; Pregnancy breastfeed Immunosuppression include concurrent condition require continue use systemic topical steroid near injection site [ deltoid , upper arm ] ( exclude inhale eye dropcontaining corticosteroid ) use immunosuppressive agent . All corticosteroid must discontinue &gt; 4 week prior Day 0 study vaccine administration ; autoimmune disorder , transplant recipient ; History previous therapeutic HPV vaccination ( individual immunize license prophylactic HPV vaccine ( e.g . Gardasil® , Cervarix® ) exclude ) ; Positive serological test hepatitis C virus hepatitis B virus surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) Administration blood product within 3 month enrollment Administration license vaccine within 2 week enrollment ( 4weeks measles vaccine ) Participation study investigational compound device within 30 day sign informed consent ; Cardiac preexcitation syndrome ( WolffParkinsonWhite ) ; History seizure ( unless seizure free 5 year ) ; Tattoos , scar , active lesions/rashes within 2 cm intend site vaccination/EP implantable lead ; implantable lead ; Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement ; Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( i.e . infection disease ) illness must enrol study ; Any condition judge investigator would limit evaluation subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CIN 2/3 CIN 3</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Papillomavirus</keyword>
</DOC>